Continues success for Attana’s customer Dr. Mads Daugaard who has received a prestigious award to continue his research against childhood cancer

Dr. Daugaard and Prof. Salanti at University of Copenhagen have previously made a ground breaking discovery that malaria proteins can be used as cancer drugs. Attanas cell-based technology played an important role in that discovery. 

Cancer researcher Dr. Mads Daugaard has been awarded with the St. Baldrick’s Foundation Robert J. Arceci Innovation Award to support his research in childhood cancer treatments. Dr. Daugaard in collaboration with the team of Prof Ali Salanti at the Centre for medical Parasitology, University of Copenhagen published their groundbreaking discovery "Targeting Human Cancer by a Glycosaminoglycan 
Binding Malaria Protein
" in the journal Cancer Cell in 2015. Since then their research has been a series of several successes and are now being commercialized in the company Var2 Pharmaceuticals. 

Dr. Daugaard comments on the award: “A very happy marriage between two research fields, namely parasitology and cancer biology.” This collaboration between disciplines led to a discovery that “could be used to treat between 50 and 100 % of different types of solid tumors.” 

The discovery also showed promising potential as a cancer vaccine. In the paper "Virus-like particle display of HER2 induces potent anti-cancer responses" published in 2018 in OncoImmunology, the same concept was demonstrated to work as vaccine in mice. 

In 2016, the team also published the first paper on kinetic analysis of the interaction of the drug molecule with solid tumors using Attana’s technology, "Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting" in Sensing and Bio-sensing Research. 

The same team has four more Attana enabled publications, which can be found in the Attana full publication list. 

At Attana, we wish Dr. Daugaard all success with the new possibilities that are opening up thanks to the award and look forward to more successful research.

 

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com

Tags:

About Us

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.

Subscribe

Media

Media

Documents & Links